{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:42:22Z","timestamp":1792669342134,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.09.3116","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:11:09Z","timestamp":1790687469000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: An Economic Evaluation"],"prefix":"10.1016","author":[{"given":"Don","family":"Husereau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Hviid","family":"Hahn-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Kettle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Luckevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"L\u00fcbker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren","family":"Mattke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jval.2026.09.3116_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.jval.2026.09.3116_bib4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jval.2026.09.3116_bib5","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.jval.2026.09.3116_bib6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jval.2026.09.3116_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"10.1016\/j.jval.2026.09.3116_bib8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jval.2026.09.3116_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2026.09.3116_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jval.2026.09.3116_bib11","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"10489","key":"10.1016\/j.jval.2026.09.3116_bib12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"issue":"6S","key":"10.1016\/j.jval.2026.09.3116_bib13","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jval.2019.04.1915","article-title":"Novel approaches to value assessment within the cost-effectiveness framework","volume":"22","author":"Garrison","year":"2019","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2026.09.3116_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14744\/AnatolJCardiol.2025.5602","article-title":"From metabolic syndrome to cardiovascular\u2013kidney\u2013metabolic syndrome and systemic metabolic disorder: a call to recognize the progressive multisystemic dysfunction","volume":"29","author":"\u00d6zy\u00fcnc\u00fc","year":"2025","journal-title":"Anatol J Cardiol"},{"issue":"4","key":"10.1016\/j.jval.2026.09.3116_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ekir.2019.01.005","article-title":"Prevalence and demographics of CKD in Canadian primary care practices: a cross-sectional study","volume":"4","author":"Bello","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.jval.2026.09.3116_bib19","doi-asserted-by":"crossref","first-page":"E429","DOI":"10.9778\/cmajo.20190212","article-title":"Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study","volume":"8","author":"Swain","year":"2020","journal-title":"CMAJ Open"},{"issue":"7","key":"10.1016\/j.jval.2026.09.3116_bib20","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.jval.2026.09.3116_bib21","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.clinthera.2021.07.015","article-title":"Prevalence of chronic kidney disease in type 2 diabetes: the Canadian REgistry of chronic kidney disease in diabetes outcomes (CREDO) study","volume":"43","author":"Chu","year":"2021","journal-title":"Clin Ther"},{"issue":"702","key":"10.1016\/j.jval.2026.09.3116_bib22","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.3399\/bjgp20X713897","article-title":"Impact of multimorbidity on healthcare costs and utilisation: a systematic review of the UK literature","volume":"71","author":"Soley-Bori","year":"2020","journal-title":"Br J Gen Pract"},{"issue":"6","key":"10.1016\/j.jval.2026.09.3116_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1524-4733.2007.00199.x","article-title":"Productivity costs associated with cardiometabolic risk factor clusters in the United States","volume":"10","author":"Sullivan","year":"2007","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.09.3116_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1186\/s12889-025-21905-2","article-title":"Modeling the cost of inaction in treating obesity in Canada","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Public Health"},{"issue":"10","key":"10.1016\/j.jval.2026.09.3116_bib25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jval.2025.07.007","article-title":"Comprehensive access to semaglutide: clinical and economic implications for Medicare","volume":"28","author":"Dayer","year":"2025","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2026.09.3116_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/oby.22696","article-title":"The societal value of broader access to antiobesity medications","volume":"28","author":"Kabiri","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jval.2026.09.3116_bib27","series-title":"Social impact of innovative medicines: a systematic approach to capture the societal and macroeconomic dimension of medicines. A meta study for Novartis","author":"Schiener","year":"2021"},{"key":"10.1016\/j.jval.2026.09.3116_bib28","series-title":"Obesity facts","year":"2025"},{"key":"10.1016\/j.jval.2026.09.3116_bib30","series-title":"World Obesity Atlas 2025","year":"2025"},{"issue":"7755","key":"10.1016\/j.jval.2026.09.3116_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41586-019-1171-x","article-title":"Rising rural body-mass index is the main driver of the global obesity epidemic in adults","volume":"569","author":"Bixby","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jval.2026.09.3116_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.pcd.2025.06.006","article-title":"Pattern of semaglutide prescription in a real-world Canadian patient cohort","volume":"19","author":"Farahvash","year":"2025","journal-title":"Prim Care Diabetes"},{"issue":"17","key":"10.1016\/j.jval.2026.09.3116_bib34","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1001\/jama.289.17.2230","article-title":"Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing","volume":"289","author":"Tishler","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jval.2026.09.3116_bib35","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1007\/s11695-020-05196-7","article-title":"Obstructive sleep apnea in obese patients: a UK population analysis","volume":"31","author":"Erridge","year":"2021","journal-title":"Obes Surg"},{"issue":"4","key":"10.1016\/j.jval.2026.09.3116_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0749-3797(03)00218-6","article-title":"Relationships between body mass indices and surgical replacements of knee and hip joints","volume":"25","author":"Wendelboe","year":"2003","journal-title":"Am J Prev Med"},{"issue":"9","key":"10.1016\/j.jval.2026.09.3116_bib38","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/oby.23842","article-title":"Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity","volume":"31","author":"Wilkinson","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"7258","key":"10.1016\/j.jval.2026.09.3116_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2026.09.3116_bib40","series-title":"Data on File\u2014SUSTAIN 6, NN9536-Exploratory, Clinical Trial Report","year":"2021"},{"issue":"1","key":"10.1016\/j.jval.2026.09.3116_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jval.2026.09.3116_bib42","series-title":"Data on File\u2014STEP 5, NN9536-Exploratory, Clinical Trial Report","year":"2021"},{"key":"10.1016\/j.jval.2026.09.3116_bib43","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.13.04088","article-title":"Incidence and temporal trends in type 2 diabetes by weight status: a systematic review and meta-analysis of prospective cohort studies","volume":"13","author":"Yu","year":"2023","journal-title":"J Glob Health"},{"issue":"9","key":"10.1016\/j.jval.2026.09.3116_bib44","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"Hayes","year":"2013","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jval.2026.09.3116_bib45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2026.09.3116_bib46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/jvh.12639","article-title":"Cost-effectiveness of elbasvir\/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States","volume":"24","author":"Elbasha","year":"2017","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.jval.2026.09.3116_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40258-023-00839-z","article-title":"Exploratory approach to incorporating carbon footprint in Health Technology Assessment (HTA) modelling: cost-effectiveness analysis of health interventions in the United Kingdom","volume":"22","author":"Kindred","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"10.1016\/j.jval.2026.09.3116_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002623","article-title":"Life cycle environmental emissions and health damages from the Canadian healthcare system: an economic-environmental-epidemiological analysis","volume":"15","author":"Eckelman","year":"2018","journal-title":"PLOS Med"},{"key":"10.1016\/j.jval.2026.09.3116_bib49","series-title":"NovoPen\u00ae Vol. 4 incl. Penfill\u00ae and needle. Novo Nordisk","year":"2023"},{"issue":"9","key":"10.1016\/j.jval.2026.09.3116_bib50","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s40273-023-01246-x","article-title":"Associating health-related quality-of-life score with time uses to inform productivity measures in cost-effectiveness analysis","volume":"41","author":"Jiao","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2026.09.3116_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3138\/canlivj-2021-0030","article-title":"Current considerations for clinical management and care of non-alcoholic fatty liver disease: insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)","volume":"5","author":"Sebastiani","year":"2022","journal-title":"Can Liver J"},{"issue":"7","key":"10.1016\/j.jval.2026.09.3116_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.jval.2026.09.3116_bib60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.15353\/cjds.v8i3.506","article-title":"Comparing integration and inclusion between Canadians and Americans with disabilities: evidence from national surveys of time use","volume":"8","author":"Wilson","year":"2019","journal-title":"Can J Disabil Stud"},{"issue":"1","key":"10.1016\/j.jval.2026.09.3116_bib61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/oby.22657","article-title":"The environmental foodprint of obesity","volume":"28","author":"Magkos","year":"2020","journal-title":"Obesity (Silver Spring)"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526057657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526057657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:09:16Z","timestamp":1792667356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526057657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S1098301526057657"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.09.3116","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: An Economic Evaluation","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.09.3116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}